-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Lkz58BVxcwky8sy+jA5wqz62GFie2bRUkm6PGsRkXrRhHeeD28bfvO0nnt/2GiKl 8Yja5JCDQRMn+Iw0dgdd1w== 0001193125-08-073089.txt : 20080402 0001193125-08-073089.hdr.sgml : 20080402 20080402115815 ACCESSION NUMBER: 0001193125-08-073089 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080214 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities FILED AS OF DATE: 20080402 DATE AS OF CHANGE: 20080402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HELIX BIOMEDIX INC CENTRAL INDEX KEY: 0000831749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 912099117 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 033-20897 FILM NUMBER: 08732015 BUSINESS ADDRESS: STREET 1: 22118 20TH AVE SE STREET 2: SUITE 204 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 425 402 8400 MAIL ADDRESS: STREET 1: 22118 20TH AVE SE STREET 2: SUITE 204 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: CARTEL ACQUISITIONS INC DATE OF NAME CHANGE: 19890718 FORMER COMPANY: FORMER CONFORMED NAME: CARIBBEAN ACQUISTIONS INC DATE OF NAME CHANGE: 19880725 8-K/A 1 d8ka.htm AMENDMENT TO FORM 8-K Amendment to Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 14, 2008

 

 

HELIX BIOMEDIX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   033-20897-D   91-2099117

(State or other jurisdiction

of incorporation or organization)

   (Commission File Number)  

(IRS Employer

Identification No.)

22118 20th Avenue S.E., Suite 204

Bothell, Washington 98021

(425) 402-8400

(Address and telephone number of registrant’s principal executive offices)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

Item 3.02 Unregistered Sales of Equity Securities.

Helix BioMedix, Inc. (the “Company”) is filing this Form 8-K/A to correct a typographical error contained in its Current Report filed on Form 8-K which was filed with the Securities and Exchange Commission on February 21, 2008 (the “Current Report”). Specifically, the Current Report incorrectly reported that in the event the Company does not consummate an equity financing with proceeds to the Company of at least $5,000,000 on or before June 29, 2008, the Company shall issue to RBFSC, Inc. (“RBFSC”) a warrant to purchase that number of shares of the Company’s Common Stock equal to 20% of the principal amount of the convertible promissory note issued to RBFSC divided by the per share closing sales price of the Company’s Common Stock on the date of issuance (the “Warrant”). Instead, the Current Report should have reported that the Warrant shall be issuable to RBFSC to purchase that number of shares of the Company’s Common Stock equal to 25% of the principal amount of the convertible promissory note issued to RBFSC divided by the per share closing sales price of the Company’s Common Stock on the date of issuance. The same typographical error was contained in the Company’s Form 10-K filed with the Securities and Exchange Commission on March 21, 2008. No other items or disclosures in the Current Report are being amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      HELIX BIOMEDIX, INC.
Dated: April 2, 2008     By:   /s/ R. Stephen Beatty
      R. Stephen Beatty
      President and Chief Executive Officer
 -----END PRIVACY-ENHANCED MESSAGE-----